DA
EGRX

Denali Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Denali Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-26,600
Closed -$139K – 471
2024
Q1 		$139K Hold
26,600
– – 0.04% 255
2023
Q4 		$139K Sell
26,600
-5,700
-18% -$56.3K 0.04% 256
2023
Q3 		$509K Buy
32,300
+11,100
+52% +$199K 0.18% 138
2023
Q2 		$412K Buy
21,200
+19,200
+960% +$455K 0.14% 157
2023
Q1 		$56.7K Hold
2,000
– – 0.02% 213
2022
Q4 		$58.5K Buy
+2,000
New +$63.6K 0.02% 207

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Denali Advisors's EGRX Position: Q2 2024 in Review

Denali Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 26,600 shares — an estimated $139K sold.

Denali Advisors first reported a position in EGRX in Q4 2022 and held it in 6 quarters. The position peaked at $509K in Q3 2023. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

  • Denali Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Denali Advisors sold 26,600 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $139K.
  • Denali Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2022 and held it in 6 quarters.
  • Denali Advisors's Eagle Pharmaceuticals, Inc. position peaked at $509K in Q3 2023.
  • 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Denali Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.